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Acute respiratory distress syndrome (ARDS) is a pulmonary disease that causes 
hypoxemia and respiratory failure. The mortality rate for ARDS ranges between 27% and 
45%. Current treatments including mechanical ventilation and extracorporeal membrane 
oxygenation (ECMO) are often associated with high risk complications including 
barotrauma, infection, thrombosis, and hemorrhage. Alternative pulmonary support 
techniques are needed to improve the survival rate of patients suffering from ARDS. 
Previous studies introducing pure O2 gas, perfluorocarbons and red blood cells into the 
intraperitoneal (IP) cavity have reported no effect or only a mild increase in oxygenation. 
Here we report peritoneal membrane oxygenation (PMO) using phospholipid-coated 
oxygen microbubbles (OMBs). OMBs are oxygen carriers that have unique physical and 
chemical properties. We hypothesize that IP infusion of OMBs can provide 
supplementary oxygenation for rats with ARDS and hypoxemia, thus allowing time for 
essential recovery of the lungs. 
We designed a bolus delivery device that automatically and periodically infuses 
OMBs to the rat’s IP cavity. In addition, the device flushes the cavity with saline, 
scavenges the perfusate, maintains safe intra-abdominal pressure, and regulates perfusate 
temperatures to body temperature.  
In order to understand the mechanism by which intraperitoneal OMB infusion 
improves systemic oxygenation, we examined, both in theory and in vivo, the kinetics of 
oxygen transport from OMBs to blood capillaries of healthy rats. A 1D mathematical 
model was developed using Fick’s laws to predict the oxygen diffusion rate across the 
peritoneum. In vivo measurements of the gas content of OMBs after 20 minutes of dwell 
time in the IP cavity of rats were further used to determine the oxygen diffusion rate, 
which was found to be within the predicted range. Also, we are able to demonstrate in 
vivo that OMBs not only can provide O2 to the body, but also can absorb CO2 and 
possibly other gases, such as N2, from the body. PMO represents an alternative 
extrapulmonary technique of oxygenation and ventilation that is a potential treatment for 
acute respiratory failure in the future. 
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Chapter 1:  Introduction 
Acute respiratory failure is a life threatening condition in which the respiratory 
system fails in one or both of its gas exchange functions, which include oxygenation and 
CO2 elimination [1] [2]. Treatment of patients with severe respiratory failure requiring 
mechanical support is done in an intensive care unit. Acute respiratory distress syndrome 
(ARDS) is the most severe form of acute lung injury. It is a rapidly progressive disease 
that leads to low oxygen levels in blood known as hypoxemia. According to a study in 
2005, about 190,000 people in the U.S. develop ARDS annually [3]. Many people who 
develop ARDS do not survive due to its high mortality, which can be as high as 45% [4]. 
The risk of death increases with age and severity of illness. Of the people who do survive 
ARDS, some recover to near-normal function while others experience lasting damage to 
their lungs. In this study we explore a possible way of oxygenation hoping that this 
technique may be useful to decrease the morbidity and mortality of patients suffering 
from ARDS in the near future. 
 
1.1 Scope and Organization of Thesis 
Chapter one focuses on the background knowledge on ARDS required to 
understand the motivation behind this study. Chapter two describes the experimental 
design and results for finding a reliable way to remove oxygen microbubbles (OMBs) 
from the intraperitoneal (IP) cavity after injection. Chapter three describes the design and 
development of an automatic oxygen microbubble (OMB) delivery device, which can be 
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used for testing the effectiveness of peritoneal membrane oxygenation (PMO) as a 
treatment for ARDS rats. Chapter four includes the modeling work done to predict the 
kinetics of oxygen diffusion from OMBs to venous blood in peritoneum tissue. Chapter 
five describes in vivo experiments for gas analysis of OMBs after injection to the IP 
cavity of rats. Chapter five is a discussion of the findings and conclusions. 
 
1.2 Acute Respiratory Distress Syndrome 
1.2.1 Pathophysiology of ARDS 
The human lungs are a pair of spongy, air-filled respiratory organs located on either 
side of the thoracic cavity in the chest. At the microscopic level are small air sacs called 
alveoli (Figure 1.1 a). Between the walls of the alveoli is a thin layer of cells called the 
interstitium, which contains cells, fibers, and blood vessels that help support the alveoli. 
The thickness of the alveolar-capillary barrier is 0.65 µm [5]. The total surface area of the 
alveoli is approximately 75 m2 in humans, which is similar to the surface area of a tennis 
court [6]. Oxygen diffuses from the air in the alveoli to the blood in the small capillaries 
surrounding the alveoli, while CO2, a waste product of metabolism, diffuses from the 
blood to the alveoli, where it can be exhaled.  
At the microstructure level, ARDS affects the alveoli in the lungs. Direct or 
indirect lung injury initiates an inflammatory-immune response that activates neutrophils, 
macrophages, and platelets to the injured sites [7]. Circulating neutrophils adhere to the 
endothelium of pulmonary capillaries and release chemical mediators resulting in damage 
to the alveolo-capillary membrane allowing fluid release from the capillary filling the 
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alveolar space [8]. When protein rich edema fluid accumulates in the alveolar space, this 
obstructs the lungs from oxygenating the blood thus leading to hypoxemia (Figure 1.1b). 
In addition, neutrophils pass through the leaky capillaries and produce an inflammatory 
response in the lung epithelium, resulting in further damage to the lungs and respiratory 
decompensation [9]. The release of inflammatory mediators from damaged lung tissue 
triggers a systemic inflammatory immune response causing multi-organ failure, which is 
the main cause of death in ARDS patients [10].  
 
 
Figure 1.1 Lung alveoli (a) normal and (b) ARDS 
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Radiographically, a chest X-ray shows bilateral diffuse infiltrates occupying most 
of the lung fields indicating ARDS (Figure 1.2b). A normal chest X-ray shows clear lung 
fields (Figure 1.2a). 
 
 
Figure 1.2 Chest X-ray (a) normal patient showing clear lung fields and (b) patient with 
ARDS showing bilateral diffuse infiltrates [11] [12] 
 
There are several causes of ARDS. Infectious etiologies such as sepsis, 
bacteremia and severe pneumonia are the most prominent. Systemic inflammatory 
conditions such as severe pancreatitis can also lead to ARDS. Inhalation of toxic 
chemicals or smoke can cause ARDS by direct injury to the alveoli and capillaries. In 
addition, traumatic injuries to the head or chest could contribute to the etiology of ARDS.  
 
5 
 
1.2.2 Available Treatment for ARDS 
The first goal in treating ARDS is to improve the levels of oxygen in the blood to 
prevent organ failure. For mild disease, oxygen may be delivered through a mask that fits 
tightly over the nose and mouth to provide supplemental oxygenation. Most people with 
moderate or severe ARDS will need to be intubated and placed on a mechanical 
ventilator (MV) to either support or completely control the breathing of the patient 
(Figure 1.3a) [13]. MV pushes air into the lungs and forces some of the fluid out of the 
air sacs. It is currently the best treatment option available. However, MV does have side 
effects. Some patients experience alveolar hyperdistention and cyclic closing and 
reopening of the alveoli during positive pressure ventilation that leads to volutrauma 
(increased lung volume) and barotrauma (increased lung pressure). These traumatic 
changes in lung volume and pressure can lead to ventilator associated lung injury 
(VALI). VALI can then trigger a pulmonary and systemic inflammatory reaction that 
may lead multiple organ dysfunction and multiple system organ failure [10]. Although 
the mortality rate of respiratory illnesses decreased over recent years due to the advances 
in MV, it still remains high [14].  
To support patients with severe ARDS who have failed MV or other conventional 
ventilator rescue techniques, researchers looked into the idea of extrapulmonary 
ventilation to bypass the damaged lungs and supply oxygen directly to the blood while 
allowing the lung injury to heal. Extracorporeal membrane oxygenation (ECMO) is an 
extracorporeal technique of providing respiratory support to patients whose lungs are 
unable to provide an adequate amount of gas exchange to sustain life [15]. This method 
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pumps blood out from the body into a diffusion membrane, artificially adding oxygen 
into the red blood cells (RBCs) and removing CO2, and then pumps blood back to the 
patient (Figure 1.3b). ECMO was first introduced in the 1970’s [16]. Historically, ECMO 
use has centered on neonatal care [17]. A recent increase in adult ECMO use can be 
attributed to H1N1-induced ARDS across the globe. It is commonly used as a last resort 
treatment in patients suffering from very severe ARDS. The survival rate of ECMO is 
47.7% [18]. ECMO is an invasive technique that has a high cost and complexity, which 
restrict its use in ambulatory situations. In addition, it is associated with high risk 
complications such as infection, thrombosis and hemorrhaging [19]. ECMO can support 
gas exchange in patients failing conventional mechanical ventilation, but proper patient 
selection and ultimate poor outcomes makes its use controversial. Therefore, alternative 
pulmonary support techniques are needed to improve the survival of patients with ARDS. 
 
 
Figure 1.3 Available treatment for ARDS patients. (a) Mechanical ventilation and (b) 
ECMO 
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1.2.3 Classification and Prognosis of ARDS 
In 2011 a panel of experts established the Berlin criteria to classify ARDS (Table 
1.1). ARDS was best classified as mild, moderate and severe based on the ratio of partial 
pressure of arterial oxygen and fraction of inspired oxygen (PaO2/FiO2) [20]. This 
classification was also based on prognostic measures. As shown in the table below, the 
mortality rate and duration of mechanical ventilation is proportional to the severity of 
ARDS and PaO2/FiO2 ratio. Patients with severe disease having the highest oxygen need 
have a high mortality up to 45% and spend on average 9 days on the ventilator, while 
patients with mild disease have a lower mortality of 27% and spend an average of 5 days 
on the ventilator.  
 
Table 1.1 Berlin criteria for defining ARDS [20] 
ARDS PaO2/FiO2 Mortality (95% CI) 
Duration on Mechanical 
Ventilation (days) 
Mild ≤ 300 27% (24-30) 5 
Moderate ≤ 200 32% (29-34) 7 
Severe ≤ 100 45% (42-48) 9 
 
1.3 Peritoneal Membrane Oxygenation  
Alternative extrapulmonary respiration methods have been explored, such as 
peritoneal membrane oxygenation (PMO). This idea was first proposed in 1934 to 
mechanically ventilate the peritoneal cavity with oxygen [21]. This idea translates from 
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the concept of peritoneal dialysis. Peritoneal dialysis is a well-known technique that has 
been widely accepted for the treatment of end stage renal failure since 1923 [22]. This 
technique exchanges solute and fluid across the peritoneum and is simple and less 
expensive than hemodialysis (Figure 1.4) [23]. The most common complications from 
peritoneal dialysis include infection around the catheter site or infection of the lining of 
the abdominal wall also known as peritonitis.  
 
 
Figure 1.4 Peritoneal dialysis [24] 
 
The peritoneum is a thin, continuous, translucent membrane, which covers the 
visceral organs and the abdominal wall. It is composed of a mesothelial single cell layer, 
interstitial tissue and blood capillaries. The average surface area of the peritoneum 
membrane (PM) is 1.3 m2 in adults [25]. PMO follows the same concept as dialysis, but 
uses the peritoneum for gas exchange. This method shows promise as it is a simple 
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procedure with easy access of the peritoneal cavity for catheterization, and relative safety 
with low risk complications compared to an extracorporeal circuit [26] [27]. 
One study observed the effects of transperitoneal ventilation with pure O2 gas on 
death time in asphyxiated rabbits [28]. All animals died successively after asphyxia. In 
addition, there was no significant increase in PaO2. This study failed because the surface 
area was minimized owing to the high surface free energy (~73 mJ/m2) of the gas/water 
interface. Another study aimed to determine whether systemic oxygenation could be 
increased in pigs, with induced hypoxia, by perfusing the abdominal cavity with 
oxygenated perfluorocarbons (PFCs) [29]. The most clinically relevant results occurred at 
an FiO2 of 14%, resulting in a baseline mean PaO2 of 39.4 ± 5.0 mm Hg with oxygenated 
saline solution perfusion, and a mean PaO2 of 55.3 ± 7.6 mm Hg with oxygenated PFC 
perfusion. Infusion of RBCs into the intraperitoneal (IP) cavity of dogs resulted only a 
mild increase in oxygen partial pressures [30]. These prior attempts have not been able to 
show clinically relevant results. This may be due to the low biocompatibility and low 
oxygen transfer efficiencies of the oxygen carrier utilized, which might explain their 
failure to oxygenate the body. The most successful application of peritoneal oxygenation 
used liposomal synthetic hemoglobin, which produced a mean increase in rat cardiac 
arrest time following a right pneumothorax from 9 to 33 min [31]. 
Our proposed solution is to us oxygen microbubbles (OMBs), an innovative 
oxygen carrier with unique physical and chemical properties. The original clinical 
utilities of gas-filled particles are as ultrasound contrast agents filled with an inert 
insoluble gas and drug delivery vehicles [32]. Such suspensions are not well suited for 
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gas delivery because they are typically designed to have low gas fractions and prolonged 
circulation. However, OMBs (70% vol) are designed to be smaller than 15 μm in 
diameter suspended in saline (30% vol). They contain pure O2 gas core encapsulated by a 
phospholipid monolayer composed of 1,2-distearoyl-sn-glycero-3-phosphocholine 
(DSPC) and polyethylene glycol (PEG) brush combined in a 9:1 molar ratio (Figure 1.5). 
PEG forms coils (~10 nm in height) that provide steric repulsion to prevent microbubble 
coalescence. The phospholipid monolayer membrane is 3 nm thick, which reduces 
surface tension and provides rigidity. The bubble’s shell comprises only ~1% of the total 
microbubble volume. OMBs mimic the structure and composition of natural lung alveoli. 
The bubble shell is highly permeable to O2 and other gases, allowing continuous diffusive 
exchange with surrounding dissolved gases [33].  
 
 
Figure 1.5 (a) OMB vial and (b) microstructure of OMBs [34] 
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A 70% volume suspension of OMBs at atmospheric pressure and 37 °C contains 
an estimated 0.88 mg-O2/mL [34]. Table 1.2 compares the oxygen carrying capacity of 
RBCs, PFCs, liposomal hemoglobin (Hb), and pure oxygen gas. OMBs can carry oxygen 
0.88 mg-O2/mL, which is higher than other aqueous carriers used at same temperature 
and pressure. Although pure O2 gas has 1.26 mg-O2/mL, the oxygen carrying capacity is 
not the only criterion for efficient oxygen transport. Oxygen diffusion also depends on 
the surface area by Fick’s law relation. The overall rate of diffusion of gas is equal to the 
product of the flux and area. Pure oxygen gas in the peritoneal cavity has a high surface 
free energy (~73 mJ/m2) of the gas/water interface. Thus, the surface area for diffusion is 
drastically minimized [34].  
 
Table 1.2 Oxygen carrying capacity at body temperature and atmospheric pressure 
O2 carrier OMBs RBCs Liposomal Hb PFC O2 gas 
Capacity 
(mg-O2/mL) 
0.88 0.31 0.62 0.57 1.26 
 
A recent study by Kheir et al. [35] characterized the release kinetics of O2 gas 
from OMBs to blood. When OMBs were mixed with human deoxygenated blood ex vivo, 
O2 diffusion was complete within only 4 sec. They also investigated intravenous injection 
of OMBs in rabbit hypoxic ventilation and tracheal clamp asphyxiation. OMBs supplied 
the animals’ full oxygen consumption for 15 min, and decreased the incidence of cardiac 
arrest and organ injury from asphyxia. The intravenous treatment with OMBs appears to 
be a promising method for short-term rescue. However, prolonged continuous infusion of 
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OMBs into the bloodstream has risks of embolism, thrombosis, and toxicities of lipid and 
saline that remains in blood circulation. Therefore, a different approach is needed for 
long term therapy of ARDS avoiding complications associated with injection of OMBs 
into the bloodstream. 
Previous work has shown that OMBs delivered intraperitoneally maintain 
hemoglobin oxygen saturations at normal levels and provide 100% survival for rats with 
a right-sided pneumothorax for at least 2 hours. In comparison, untreated rats and rats 
treated with peritoneal oxygenated saline died within 30 min [34]. Another study showed 
that PMO therapy can double the survival time of rabbits after complete tracheal 
occlusion from 6.6 ± 0.6 min (average ± SD) for the saline controls to 12.2 ± 3.0 min for 
the bolus OMB treated rabbits [36]. These results show that OMBs have potential to be 
an alternative mechanism of oxygen delivery when injected intraperitoneally.  
Previous work characterized the properties of OMBs ex vivo [37] [33], but there is 
a need to conduct research to study the rate of oxygen delivery in vivo. Also further 
studies are needed to test the potential of OMBs in absorbing CO2 in vivo. Our team 
recently demonstrated that PMO can significantly increase survival in rats suffering a 
right pneumothorax and rabbits suffering complete tracheal occlusion. In order to proceed 
into a more clinically relevant disease model, the goal of the proposed study is to develop 
and test PMO therapy in a clinically relevant rat model of mild to severe ARDS in rats. 
We hypothesize that intraperitoneal infusion of OMBs can be used as a supplementary 
method of oxygen delivery and CO2 removal for rats with ARDS thus allows time for 
essential recovery of the lungs.  
13 
 
1.4 Research Objectives 
The overall goal of this research is to considerably increase the survivability of 
patients with ARDS by providing alternative extrapulmonary oxygenation using OMBs. 
In pursuit of this goal, the specific aims of this research is to first finalize the 
development and validation of an OMB delivery system that will automatically infuse 
and remove OMBs from the rat’s IP cavity. This device can be used for a long term study 
for testing PMO as a potential treatment for ARDS in rats. 
We aim to understand the mechanism by which intraperitoneal OMB infusion 
improves systemic oxygenation, by examining the OMB gas exchange properties with the 
PM by both theoretical modeling and in vivo tests. A one dimensional mathematical 
model developed using Fick’s laws can predict the oxygen transport rate from OMBs to 
peritoneum blood. A model would help us understand in theory the kinetics of oxygen 
transport and how that would relate to the normal oxygen consumption need in rats. In 
addition, it can predict whether continuous infusion or periodic bolus infusion of OMBs 
is more efficient in oxygen delivery. One way for experimental validation of the model is 
by measuring O2 delivery and CO2 removal by OMBs after infusion to the IP cavity of 
rats. These measurements can be used to calculate the oxygen diffusion rate in vivo and 
compared to our modeled oxygen kinetics. Finally, we aim to determine the optimal 
perfusion dosage and dwell time of OMBs in the IP cavity of rats. 
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Chapter 2:  Aspiration of OMBs from the 
Intraperitoneal Space 
2.1 Introduction 
Injection of OMBs into the IP cavity of rats can be applied by a needle or a 
catheter implanted in the lower abdomen. The purpose of this experiment is to find a 
reliable aspiration technique of OMBs after an IP injection. Aspiration is needed in 
experiments involving studying the gas content of OMBs after dwelling in the IP space. 
In addition, IP infusion of OMBs for several days to treat ARDS will lead to 
accumulation of saline and lipids in the IP cavity. If intra-abdominal pressure exceeds 
safe limits this could interfere with the hemodynamics of the abdomen and limit the 
blood supply to abdominal organs. In order to prevent inducing abdominal compartment 
syndrome, OMBs need to be removed from the IP space. Previous attempts by our group 
to aspire the injected OMBs after dwelling in rat’s IP cavity were unsuccessful using 
small needles. In this experiment, different needle diameters were tested, in addition to a 
side opening teat tube (SOTT), and a peritoneal lavage catheter (PLC) (Figure 2.1a,b). 
 
2.2  Materials and Methods 
Male Wistar rats (n = 5, m = 539 g) were housed and acclimated for four days, 
and cared for according to the University of Nebraska-Lincoln Institutional and Animal 
Care and Use Committee (IACUC) guidelines. All rats were sedated using ketamine-
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xylazine (18-2 mg/kg) and placed in the supine position on a warming pad (T/pump 
Classic, Gaymar) set at 38 °C to maintain body temperature. Paw pinches were made to 
verify full sedation. The rat was then placed in a supine position on the surgery table.  
Previous studies showed that an IP volume injection of 60 mL was considered to 
be safe for ~ 500 g rats [38] [39]. OMBs were stored in a cooled environment at 5 °C 
prior to the experiment to preserve their composition and structure. A 60 mL syringe was 
used to extract OMBs from the vial, and the syringe was left at room temperature for 5 
minutes. A 60 mL single bolus of OMBs was injected into the IP cavity within 1 minute. 
After injection, OMBs were allowed to dwell for 2 minutes so that OMBs were naturally 
distributed inside the cavity. After dwell, OMBs were manually aspirated by pulling out 
the plunger of the syringe. The volume of OMBs aspirated was recorded, and the 
aspirated OMBs were transferred into a waste beaker. The same volume of fresh OMBs 
was injected in the IP cavity using the next larger needle and allowed to dwell for 2 
minutes. This preserves a total of 60 mL OMBs in the IP cavity. Three different methods 
were tested, which include needles of increasing size (18G, 16G, 14G, 11G, and 10G), an 
SOTT, and a PLC (JP7, Mila International, Erlanger, KY) catheter were tested. Table 2.1 
shows the inner diameter (ID) and length of the needles, SOTT, and PLC used. For the 
11G, 10G, and SOTT, a scalpel was used to make a small incision in the lower right 
quadrant of the abdominal cavity to accommodate for the larger diameters. All items 
were placed in the same incision to minimize injury to the rat. For placing the catheter, a 
small incision into the skin was made to expose the fascia of the abdominal wall. A PLC 
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outflow catheter (PLC) was surgically implanted in the IP cavity and sutured to the skin. 
Finally, the rat was sacrificed using CO2 inhalation. 
2.3 Statistical Analysis 
Multiple t-tests assuming equal variances was performed on the volumes of 
aspirated OMBs to test for any differences between all groups. All tests used the same 
level of significance (α = 0.05). 
 
 
Figure 2.1 Items tested for aspirating OMBs (a) Side opening teat tube and (b) peritoneal 
lavage catheter 
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Table 2.1 Size of the needles and catheters tested for aspiration of OMBs 
Size 
Needles Cannula Catheter 
18G 16G 14G 11G 10G SOTT PLC 
ID (mm) 0.8 1.2 1.6 2.4 2.7 1.5 7 
Length (cm) 2 3.8 2.5 2 2 6 20 
 
2.4 Results and Analysis 
The aspirated volumes of OMBs are shown in Appendix A. The means ± SD were 
plotted on a bar graph in Figure 2.2. The PLC had the highest average of aspired volume 
of 30 ± 6.3 mL. There is significant statistical difference between the means of PLC and 
each of SOTT, 10G, 14G, and 18G needles ( ‘***’ p<0.001).  
Volumes of approximately 0 mL OMBs aspirated were due to omental occlusion 
(OO). Occlusion occurs when fatty abdominal tissue (omentum) occludes the tip of the 
needle while applying a suction force using the syringe. Table 2.2 summarizes the 
frequency of OO occurrence for each item. Occurrence of omental occlusion (per 5 rats) 
was between 2 to 4 using needles (between 18G and 10G ) compared to none using the 
lavage catheter. In other words, during aspiration needles had a high failure rate of 50 – 
80%, while the PLC had 0% failure.  
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Table 2.2 Frequency of omental occlusion occurred using each item (n=5) 
Item 18G 16G 14G 11G 10G SOTT PLC 
Frequency of OO 3 2 4 3 3 1 0 
 
 
Figure 2.2 Aspiration volumes (mean ± SD) of OMBs using different items. Significant 
difference is indicated by ‘***’ (p<0.001) 
 
The needles had a wide range of aspiration volumes of spent OMBs ranging from 
0 to 43 mL. The variation was mainly due to the high probability of omental plug during 
aspiration. PLC successfully aspirated an average of half of the injected OMBs, with a 
relatively low SD over the 5 trials. PLC has proven to be the most reliable and efficient 
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method to extract the OMBs. Its advantages over needles and SOTT are its flexibility, 
wider diameter, its numerous pores and increased length that allows a large surface area 
in the IP cavity and subsequently allows better aspiration of OMBs. Thus, PLC can be 
used for long term studies were it can be surgically implanted in the IP cavity unlike 
needles or SOTT. In addition, the PLC can be used in experiments that require extraction 
of OMBs from the IP space for gas content measurements.  
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Chapter 3:  OMB Infusion Device 
3.1 Introduction 
The mortality rate of patients with ARDS remains high even with the 
advancements in mechanical ventilation and ECMO. Alternative extrapulmonary 
ventilation techniques such as peritoneal membrane oxygenation are still being explored 
as a potential therapy for ARDS. With the development of a promising oxygen carrier, a 
device is needed to deliver OMBs intraperitoneally. The system will be used for studying 
PMO with conscious and ambulatory rats of mild to severe ARDS. To evaluate 
improvements of oxygen levels in blood and survivability, the length of the study will be 
at least 3 days after inducing ARDS to rats and administering OMB treatment. Manual 
infusion and removal of the perfusate to the cavity is a time consuming and exhaustive 
procedure. In addition, continuous or periodic infusion of OMBs for several days results 
in accumulation of lipids and saline (30% vol) in the IP space thus could limit the blood 
supply to abdominal organs if IP pressure exceeds safe limits. Therefore, an automatic 
system for infusion and scavenging of OMBs is needed for this study.  
The design of the delivery device was established in a manner similar to 
peritoneal dialysis catheter placement. A preliminary design was developed for 
continuous infusion of OMBs, which consisted of two catheters implanted in the cavity, 
one for inflow, and PLC for outflow. However, in vivo testing of the continuous infusion 
system first prototype revealed advanced tissue obstruction and growth in the PLC after 
four days. This was a major problem as it prevented further removal of fluid from the 
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cavity. In addition, OMBs need to dwell in the cavity for gas exchange to occur (Chapters 
4 and 5).Therefore, the design was revised to implement a periodic bolus system that is 
simpler and effective. This chapter focuses on describing the current bolus delivery 
system. The device will automatically infuse and scavenge OMBs, maintain safe intra-
abdominal pressure, and regulate perfusate temperatures to body temperature.  
3.2 Materials and Methods 
A schematic of the delivery system (Figure 3.1) includes OMB storage, periodic 
infusion of OMBs, intra-abdominal pressure (IA) pressure measurement and control, 
temperature measurement and control, tubing restraint, data acquisition and LabVIEW 
control.  
 
Figure 3.1 Schematic of the bolus delivery system for conscious rats 
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3.2.1 OMB storage 
OMBs require a cool, rotating, and pure humid O2 environment to avoid 
breakdown of the lipid monolayer in the bubbles. The OMB vial is stored in a container 
at a temperature between 2-8 ºC and placed on a rotating table. The OMB vial is 
connected to an inlet line for suppling pure O2 gas, an O2 outlet line to avoid over 
pressurizing the vial, and an OMB supply line (Figure 3.2). To avoid evaporation of the 
saline in OMBs, pure O2 gas is supplied to a closed vial containing water, which supplies 
humidified O2 gas to the OMBs vial. 
 
Figure 3.2 Humidifier for OMBs 
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3.2.2 Infusion 
The fluid infusion system necessary to supply OMBs without exposing the 
infusing fluid to the pump and surrounding atmosphere. The system delivers OMBs by a 
peristaltic pump (FH100M, Thermo Fisher Scientific, Waltham, MA) shown in Figure 
3.3. OMBs pass from the storage vial through tubing, connectors, valves, and swivel 
before reaching the cavity. This closed loop system avoids air contamination of OMBs to 
preserve their oxygen content. The system requires only a single peritoneal catheter that 
is used as both an inflow and outflow line. The PLC is tunneled subcutaneously to the 
back of the rat where they are fixed to a custom pedestal at least 3 days prior to the 
beginning of the study. The perfusion circuit includes connecting tubing to the 
infusion/scavenge ports of the PLC to the pump. The pump has a flow rate range of 
0.013-760 mL/min and a maximum output of 200 rpm. This pump has an extended rotor 
head for multiple tubing lines, which allows the ability to infuse multiple subjects or 
multiple fluids. The adjustable cartridges allow most tubing diameters to be used for 
infusing. The pump has a DB-25 input/output with 0-10 V, which allows for it to be 
controlled using a LabVIEW program. 
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Figure 3.3 Peristaltic pump used for infusion  
 
3.2.3 Pressure Measurement and Control 
In order to prevent over pressurizing the cavity that could limit blood flow to the 
region and can lead to abdominal compartment syndrome, IA pressure is measured and 
maintained between 0 – 6 mmHg [40] [41]. For measuring the IA pressure of rats non-
invasively, a pressure transducer (S7d, Gaeltec Devices Ltd, Isle of Skye, UK) is inserted 
into a catheter for continuously reading pressure throughout the length of the study. The 
sensor (6 French) is inserted into the inflow/outflow line at a negligible height over the 
catheter port to avoid inaccuracy in the IA pressure reading. 
The S7d is powered by a low voltage mains adaptor 9V DC with sensitivity of 
5μV/V/mmHg. For completely accurate pressure measurements, the transducer is 
compared to a calibrated pressure sensor. The transducer is connected to an amplifier 
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(S7d pressure transducer amplifier, Gaeltec Devices Ltd), which has an LCD display and 
is connected to a 4 channel box (Figure 3.4). Also, it has an analog voltage output port 
that can be connected to a data acquisition system.  
 
Figure 3.4 Pressure measurement and display 
 
Pressure is regulated through the use of a fluidic control solenoid valve controlled 
by LabVIEW. In case IA pressure exceeds 6 mmHg, the outflow solenoid valve opens 
and a scavenge phase is initiated so that OMBs are extracted from the IP cavity until the 
IA pressure goes back to the safe range.  
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3.2.4 Temperature Measurement and Control 
OMBs are stored at low temperatures to preserve their structure and stability for 
approximately 7-10 days. Before infusing OMBs in bolus volumes to the rat’s IP cavity, 
they need to be warmed close to body temperature to avoid inducing hypothermia. The 
fluid warmer (i-Warm, Midmark, Kettering, OH) is a dry-heat device designed for 
warming I.V. fluids safely through the heating plate (Figure 3.5). Measurements of the 
temperature of the OMBs both in their storage and after passing through the fluid warmer 
are needed to verify they are within the required ranges. To measure the temperatures, a 
K-type thermocouples are used. One sensor is placed in a T connector at the fluid warmer 
exit line. Another sensor is placed in the OMB storage to verify the temperature is 
between 2-8 ºC. The thermocouple output is amplified with an AD595-AQ amp (Burr-
Brown, Digikey, Thief River Falls, MN). The output of the amplifier is 10 °C/mV. The 
project circuit board (PCB) is designed on Altium to connect the electronics (Appendix 
B). The circuit includes two K-type thermocouples, two amplifiers, +5 V power supply, 
ground, and two voltage outputs. The PCB is then fabricated by the UNL Engineering 
Electronics Shop (Figure 3.6).  
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Figure 3.5 Fluid warmer  
 
Figure 3.6 PCB for temperature measurement 
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3.2.5 Tubing restraint 
In order to prevent tubing from restraining the rat or being damaged by the rat, a 
spring restraint is originally designed with a spring retractor and a counter balance 
weight. Preliminary trials of the first prototype revealed that this tubing restraint did not 
work properly. One rat managed to reach the tubing and pull on his catheter. Therefore, a 
new design for a rat tether is under development. 
The tubing will be tethered to the infusion pump via a custom swing arm that 
keeps the tubing suspended above the rat and prevents entanglement (Figure 3.7). Once 
in the cage, the animal will have free access to food and water. 
Tethered systems require an in-dwelling catheter, a harness, and swivel. Tethered 
infusion is a commonly employed technique in laboratory animals, especially rats. This is 
the only option for long-term continuous access in rats [42]. The rat harness serve to 
protect the catheter port and with minimal stress, a means of restraining the animal. 
In addition, a counterbalance serves to reduce the weight load that the animal 
experiences from the tether and swivel. An important component between the rat and the 
pump is the swivel, which serves as a rotary fluid seal. Without the swivel, the animal 
would be significantly encumbered in its movement, and the fluid line would occlude 
partially or totally. 
29 
 
 
Figure 3.7 Rat tether [42] 
 
3.2.6 Data Acquisition 
To connect the peristaltic pump to the DAQ (USB-6003, National Instruments, 
Austin, TX), a DB-25 break out board (Winford Engineering, Auburn, MI) is required. 
Figure 3.8 shows the electronics box that includes 4 solid state relays, a breakout board, 
DAQ, and temperature PCB. The acrylic box design using SolidWorks is shown in 
Appendix C. 
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Figure 3.8 Electronics box 
 
3.2.7 LabVIEW Control 
The delivery device includes a LabVIEW interface shown in Figure 3.9 to control 
several key parameters such as rat’s mass, pump speed, and type of infusate, which is 
either saline or OMBs. In addition, the program provides manual override that allows the 
user to control the pump and the four solenoid valves or stop the system completely. The 
control program automatically calculates the bolus volume (BV) based on the rat’s mass 
(M) as: BV (mL) = M (g) /10 
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Figure 3.9 LabVIEW control user interface  
3.2.8 Testing the System 
For preliminary trials to test the continuous system, male Wistar rats (n = 2, m ~ 
500 g) were successfully administered aerosolized (Lipopolysaccharide) LPS endotoxin 
to induce ARDS. One rat was continuously infused OMBs at 0.5 mL/min for 12 hours 
and the other for 24 hours. Another trial was conducted on a rat for 4 days for testing the 
automatic infusion and scavenging system. Benchtop tests were conducted on the final 
design of the automatic bolus system. 
 
3.3 Results and Analysis 
In ARDS rats, SpO2 decreased steadily following administration of endotoxin in 
untreated controls while SpO2 increased after 24 hours for ARDS rats treated with OMBs 
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(Figure 3.10). The device lacked automatic scavenging with a waste flow line. Instead, 
excess OMBs were removed by manually drawing them out from the cavity with a 
syringe connected to the PLC every 2 hours.  
One preliminary trial on a rat was conducted with the automatic continuous 
infusion and scavenging system and it revealed that there was advanced tissue obstruction 
and growth in the PLC after four days. This may be caused by the constant suction 
applied to the outflow line leading to suction of tissue inside the pores of the lavage 
catheter. 
Benchtop testing of the final design of the bolus delivery system has been 
successfully completed. The tubing restraint was not working properly. The new design 
of the rat tether is still under development. The bolus delivery system will be tested on 
rats to ensure that infusion and scavenging can be maintained for two weeks. Once 
testing is successful, we will proceed with validation trials with saline, inert gas 
microbubbles, and OMBs. 
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Figure 3.10 Oxygen saturation taken by pulse oximetry [43]  
  
34 
 
Chapter 4:  Diffusion Modeling 
4.1 Introduction 
A previous theoretical and experimental study was undertaken by Borden et al. to 
determine the fate of a microbubble suddenly suspended in a multi-gas environment, such 
as the bloodstream [33]. They developed a numerical model based on the classic Epstein 
and Plesset theory that predicts the rate of microbubble dissolution in a single gas 
medium. Experimental verification of the model was performed with individual sulfur 
hexafluoride (SF6) microbubbles coated with a soluble surfactant. Microbubbles placed in 
a perfusion chamber containing N2 and O2 in an aqueous medium initially grew due to 
the influx of nitrogen and oxygen and then dissolved under surface tension. 
In contrast, our study involves infusion of oxygen filled microbubbles into the 
intraperitoneal cavity of rats with ARDS. This is a new method being explored that 
requires more studies in theory and in vivo. A lack of literature on modeling oxygen 
delivery from OMBs to peritoneum tissue prompted a need for this study. In addition, 
there is not enough data that support one method of infusion in delivering oxygen (bolus 
vs. continuous circulation). A model for diffusion would predict how fast oxygen diffuses 
across the multiple layers of tissue in the surrounding abdomen. Depending on how fast 
diffusion reaches steady state, this would determine the maximum dwell duration of 
OMBs. A simple 1D mathematical model was developed using Fick’s laws to determine 
the oxygen transport rate and how it compares to the normal oxygen consumption need.  
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4.2 Materials and Methods 
For OMBs injected into the IP cavity of rats, the pathway of gas exchange across 
the PM is assumed to be homogeneous and has one spatial dimension for simplification. 
OMBs are assumed to have a constant O2 concentration when injected in the IP cavity 
and no oxygen is consumed by surrounding tissue. The gas components are assumed to 
behave ideally and no convection occurs. 
Oxygen molecules move down their concentration gradient diffusing out of 
OMBs to reach RBCs in the PM blood capillaries (Figure 4.1). To reach the capillaries in 
the peritoneum, oxygen must first dissolve in the saline of the OMBs and then diffuse 
through the mesothelium, cells and interstitial tissue. To reach the capillaries in the 
parenchymal tissue beneath the PM, oxygen must first dissolve in the saline of the OMBs 
and then diffuse through the PM layers and muscle tissue (Figure 4.2). The rate of 
diffusion depends on the surface area of the PM and the flux density. Increasing the area 
or the concentration gradient leads to faster diffusion. The diffusion rate using Fick’s first 
law is written as  
 J = −AD ( 
dC
dx
 )
x=L
= −AD
C0−Cs
L
 (1) 
where the diffusion zone is equal to the thickness (L) of the tissue between the OMBs and 
blood capillary wall, C0 and Cs are the dissolved O2 concentrations in blood capillaries 
and in the peritoneal cavity, respectively, D is the diffusivity, and A is the surface area of 
the PM, which can be calculated using the rat’s mass (M) [44] 
 𝐴(𝑖𝑛 𝑐𝑚2) = 1.61𝑀(𝑖𝑛 𝑔) + 40.5  (2) 
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The dissolved gas concentration at equilibrium depends on both partial pressure 
(P) and solubility (α) according to Henry’s law  
 𝐶 = α𝑃 (3) 
The parameters of solubility and diffusivity for O2 in plasma and tissue are 0.003 
(mL/dL)/mmHg and 1.7 x10-5 cm2/s, respectively [45]. The PM has a reported thickness 
of approximately 90 µm in rats [46]. However, because rats have relatively few blood 
vessels in the peritoneum, most oxygen transport could end in parenchymal tissue blood 
vessels, which are below the PM at a thickness between 0.5 – 1 mm [47]. Both cases are 
examined in the calculation of the diffusion rate. If diffusion occurs over the PM by 
itself, O2 will be absorbed by blood capillaries at peritoneum thickness of 90 µm (case 1). 
In contrast, if diffusion reaches the visceral organ capillaries, then the average tissue 
thickness is 0.75 mm (case 2). We used Fick’s second law [48] that predicts how 
diffusion causes the concentration (Cx) to change with time. The solution to Fick’s 
second law [48] is 
 
𝐶𝑥−𝐶0
𝐶𝑠−𝐶0
= 1 − 𝑒𝑟𝑓 (
𝑥
2√(𝐷𝑡)
) (4) 
where x is the thickness of tissue and t is time. 
MATLAB was used to solve and plot Cx (Appendix D). In addition, the oxygen 
supply from OMBs was compared to the oxygen metabolism in resting rats, which is ~12 
mL/min/kg [49]. 
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Figure 4.1 Simplified model of oxygen diffusion from OMBs to the layers of the 
peritoneum 
38 
 
 
Figure 4.2 Simplified model of oxygen diffusion from OMBs to the layers of 
parenchymal tissue 
 
4.3 Results and Analysis 
A simplified model for diffusion of oxygen from OMBs to the peritoneum blood 
was constructed. The mass of rats used in the mathematical model was 538 g, equal to the 
average mass of rats used in the in vivo experiments. Using equation 2, the peritoneal 
surface area was calculated to be 907 cm2. The oxygen partial pressure (PO2) in the 
peritoneal blood capillaries is normally 40 mmHg [50]. The average rat IP pressure 
measured after a single bolus injection of OMBs was ~2 mmHg above atmospheric 
pressure, so PO2 in OMBs was 762 mmHg. Thus, the pressure gradient of OMBs-to-blood 
was 722 mmHg.  
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The oxygen content inside OMBs is 70 mL/dL, while O2 bound to hemoglobin in 
RBCs has a concentration of 15 mL/dL within venous blood. However, the diffusion rate 
is driven by the dissolved oxygen concentration gradient. Using equation 3, the 
concentration of dissolved O2 in venous blood is C0, which is equal to 0.12 mL/dL, while 
the concentration of dissolved O2 in OMB saline is Cs, which is equal to 2.29 mL/dL. The 
OMBs-to-blood dissolved O2 concentration gradient is their difference of 2.17 mL/dL. 
An algorithm was developed using MATLAB to solve and plot the oxygen 
diffusion kinetics. If the diffusion thickness is 90 µm, then the oxygen diffusion rate 
would be 0.038 mL/s, and this supplies 34.4% of the total oxygen consumption needed in 
rats. However, if the thickness is 0.75 mm, then the diffusion rate would be 0.0045 mL/s 
supplying only 4.2% of the total oxygen consumption of rats. Tissue at depth of 90 µm 
(Figure 4.3a) will reach O2 concentration of 1.94 mL/dL within 1 minute. Steady state is 
reached after 35 seconds. Tissue at depth of 0.75 mm (Figure 4.3b), will reach O2 
concentration of 1.77 mL/dL within 30 minutes. Steady state is reached after 41.7 
minutes. 
These results show that in theory oxygen delivered by OMBs in vivo occurs at a 
range between 0.0045 and 0.038 mL/s. Since oxygen delivery requires time (up to 42 
min) to reach steady state, a bolus dosage administered periodically to IP cavity would be 
more efficient and cost effective than continuous infusion of OMBs. A 60 mL bolus 
would require a maximum dwell time of approximately 42 min to reach steady state in 
diffusion, but further in vivo tests are required to validate this dwell time. 
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Figure 4.3 Mathematical model of 1D diffusion of oxygen from OMBs to peritoneal 
blood over time 
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Chapter 5:  In vivo Study 
5.1 Introduction 
In chapter 4, we have developed a simple model that predicts oxygen delivery 
from OMBs injected intraperitoneally. In theory the oxygen diffusion rate was found to 
be between 0.0045and 0.038 mL/s. This range for diffusion rate is relatively wide due to 
several modeling limitations including 1D pathway and no oxygen consumption by tissue 
considerations. To validate our model and to obtain a more precise oxygen transport rate, 
an in vivo experiment was designed. A previous study by Kheir et al. [35] showed that 
OMBs when mixed with deoxygenated blood ex vivo deliver O2 in 4 sec. The purpose of 
this experiment is to study not only oxygen delivery by OMBs, but also possible CO2 
absorption and other gas(s) from surrounding tissue in vivo. To validate gas diffusion 
properties of OMBs in vivo, the gas content of OMBs was measured by a gas analyzer 
before and after injection to the rat’s IP cavity. Fresh OMBs ideally contain pure oxygen 
gas if handled carefully avoiding air contamination. Measured gas concentrations were 
further converted to volumes and diffusion rate and depth were calculated. The 
experimental results for diffusion were then compared to the modeled theoretical values. 
 
5.2 Materials and Methods 
Male Wistar rats (n = 4, 538 ± 48 g) were housed and acclimated for four days, 
and cared for according to the University of Nebraska-Lincoln IACUC guidelines. All 
rats were sedated using ketamine-xylazine (18-2 mg/kg) and placed in the supine position 
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on a warming pad (T/pump Classic, Gaymar, Orchard Park, NY) set at 38 °C to maintain 
body temperature (Figure 5.1a). Pulse oximetry (PhysioSuite, Kent Scientific Corp., 
Torrington, CT) measurements were taken throughout the whole experiment to measure 
the heart rate (HR) and oxy-hemoglobin saturation (SpO2). The pulse oximeter clip was 
placed on the rat’s hind leg and data was recorded every second until the experiment was 
terminated. After the rat was fully sedated and unresponsive to pain delivered by paw 
pinches, a small incision into the skin was made to expose the fascia of the abdominal 
wall. An inflow tube (3.2 mm, Tygon) and outflow catheter (JP7, Mila International Inc, 
Erlanger, KY) were surgically implanted in the IP cavity and sutured closed (Figure 
5.2b). A valve was placed on the exterior end of the outflow catheter to vacuum the line 
with a syringe. A pressure sensor (S7d, Gaeltec Devices Ltd., Isle of Skye, UK) and the 
injection syringe were connected to the inflow line. IP pressure was monitored and 
maintained below 6 mmHg to avoid disruption of hemodynamics in the rat’s abdomen 
[51] [ 40]. The gas content of a 10 mL OMB sample collected directly from the OMB vial 
was analyzed before injection (t = 0). A single 60 mL OMB bolus, a safe volume for 
intraperitoneal injection of fluid in rats [38], was infused within 1 minute into the IP 
cavity using the inflow line. Immediately after, the IP pressure was recorded. 
Subsequently, 10 mL OMB samples were collected from the IP cavity every 5 minutes. 
Samples were manually crushed in the syringe by applying pressure to the plunger and 
then placed on a heating pad (70 °C) for 10 minutes (Figure 5.1b). This technique broke 
the lipid monolayer of the OMBs and released the gas content of the sample into the 
headspace (Figure 5.2c). The gas headspace was carefully transferred to another syringe 
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to be analyzed by an O2 and CO2 headspace gas analyzer (Gaspace 6600, Illinois 
Instruments, Inc., Johnsburg, IL). The syringe containing the gas sample was introduced 
into the gas analyzer by auto-injection (Figure 5.1c and Figure 5.2d). The entire process 
avoided air contamination to get the most reliable reading. Finally, after 20 minutes and 4 
OMB samples were collected rats were euthanized by CO2 inhalation. 
One way valves were a source of inevitable air contamination added to each 
sample. The total volume of contamination, Vair, was found to be approximately 0.85 mL 
and composed of atmospheric air. A species balance was used to find the adjusted sample 
concentrations (xsample) for O2, CO2 and N2 neglecting water vapor and other trace gases. 
The overall volume balance was found with the following equations. 
 
 𝑥𝑂2,𝑠𝑎𝑚𝑝𝑙𝑒 = 𝑥𝑂2,𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑑 (
𝑉𝑎𝑖𝑟
𝑉𝑠𝑎𝑚𝑝𝑙𝑒
+ 1) − 0.21 (
𝑉𝑎𝑖𝑟
𝑉𝑠𝑎𝑚𝑝𝑙𝑒
 ) (5) 
 𝑥𝑁2,𝑠𝑎𝑚𝑝𝑙𝑒 = (1 − 𝑥𝑂2,𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑑 − 𝑥𝐶𝑂2,𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑑) (
𝑉𝑎𝑖𝑟
𝑉𝑠𝑎𝑚𝑝𝑙𝑒
+ 1) − 0.79 (
𝑉𝑎𝑖𝑟
𝑉𝑠𝑎𝑚𝑝𝑙𝑒
 ) (6) 
 𝑥𝐶𝑂2,𝑠𝑎𝑚𝑝𝑙𝑒 = 𝑥𝐶𝑂2,𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑑 (
𝑉𝑎𝑖𝑟
𝑉𝑠𝑎𝑚𝑝𝑙𝑒
+ 1) (7) 
 
5.3 Statistical Analysis 
A linear mixed model with repeated measures with AR(1) covariance structure 
followed by a t-test were performed on the estimated slopes and intercepts of recorded 
SpO2 data before injection and after injection of OMBs. A p-value threshold of 0.05 was 
considered statistically significant. 
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Figure 5.1 Experimental setup for headspace gas analysis of OMBs 
 
 
Figure 5.2 Pictures taken during experiment (a) OMB extraction (b) implanted catheters 
(c) crushed OMBs (d) headspace gas analysis 
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5.4 Results and Analysis 
Intraperitoneal pressure was recorded after OMB bolus injection. The average 
measurement was 1.93 ± 0.5 mmHg (n = 4). Before injection of OMBs at time 0 (Figure 
5.3), the rats’ average SpO2 was approximately 83.8 ± 0.8%, while the average HR was 
231.0 ± 10.3 bpm.  After OMB bolus injection and 20 minutes dwell time, SpO2 increased 
to 86.2 ± 2.2%, while HR decreased to 226.2 ± 9.0 bpm. The fitted linear regression 
model for SpO2 data showed that the slope of the line before injection was – 0.0043 
indicating that there was no change in SpO2 and had no statistically significant increase 
with time (p > 0.05). After injection of OMBs, there was a slight increase of SpO2 after 
dwell with a slope of +0.057, which was found to be statistically significant (p < 0.05) 
using the same model and statistical test. 
After crushing the OMBs, the gas volume was recorded for each sample (Figure 
5.4a).  Fresh OMBs had 67% gas volume fraction. This fraction decreased to 34.6 ± 8.2% 
after 20 minutes of dwell time.  The measured gas contents were adjusted for 
contamination using equations 5, 6 and 7. Figure 5.4b shows the adjusted gas content 
detected in OMBs before and after dwelling in the IP cavity. Fresh OMBs had an average 
of 93.8 ± 3.9%, 0% and 6.2 ± 3.9% for O2, CO2 and N2, respectively.  After 20 minutes 
of dwell time, OMBs had an average of 76.3 ± 7.7%, 5.5 ± 1.2% and 17.2 ± 7.6% for O2, 
CO2 and N2, respectively. 
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Figure 5.3 Pulse oximeter measurements (LS-mean) include (a) heart rate (beats per 
minute) and (b) oxy-hemoglobin saturation (%) before and after OMB bolus injection to 
the rat’s IP cavity (n = 4) 
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Figure 5.4 (a) Gas vol% composition (average ± SD) of OMBs and (b) gas content of 
OMBs after OMB infusion to the cavity (n = 4) 
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Gas percentages obtained by the gas analyzer were further analyzed to determine 
the volume of O2 that diffused from OMBs to the rat’s body. The calculated diffusion 
volumes of O2, CO2 and N2 across the PM over 20 min are shown in Table 5.1. Negative 
values represent diffusion in the opposite direction, from the rat’s body into the OMBs. 
OMBs in the IP cavity had a total of 16.5 mL O2 diffused over 20 minutes. This was 
equivalent to a diffusion rate of 0.014 mL/s. OMBs still carried 57.6 % of their initial O2 
volume after 20 min of dwell. Using the obtained diffusion rate, the diffusion depth was 
calculated to be 236 µm, and the oxygen supply was 13.1% of the total need. These 
values were within the range of our calculated theoretical diffusion model shown in Table 
5.2. 
These results indicate that after 20 minute dwell duration, OMBs (60 mL) still 
carry more than half of their initial oxygen content. In theory, a 45 min dwell would be 
enough time for oxygen to diffuse. These results confirm our bolus volume and dwell 
time predicted by our model in chapter 4. Therefore, for ~ 500 g rats a bolus volume of 
60 mL OMBs will be allowed to dwell for ~ 45 minutes in the IP cavity of rats. 
Additional trials are needed to test this dwell duration on hypoxic rats. 
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Table 5.1 Diffused volume (average ± SD) of gases in mL between OMBs and 
surrounding tissue during dwell in IP space (n = 4) 
Time 
(min) 
VOMBs in IP VO2 diffused 
VCO2 
diffused 
VN2 diffused 
0 60 -- -- -- 
5 60 9.8 ± 4.4 -0.4 ± 0.1 -5.2 ± 2.2 
5+ 50 -- -- -- 
10 50 -1.4 ± 5.5 -0.2 ± 0.2 2.3 ± 2.9 
10+ 40 -- -- -- 
15 40 4.4 ± 1.8 -0.2 ± 0.2 0.3 ± 0.9 
15+ 30 -- -- -- 
20 30 3.6 ± 1.8 -0.3 ± 0.2 0.3 ± 0.4 
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Table 5.2 Modeled versus experimental diffusion rate (J), diffusion depth (L) and oxygen 
supply 
 
Model Experiment 
Case 1 Case 2  
Depth (µm) 90 750 236 
Rate (mL/s) 0.038 0.0045 0.014 
% O2 supply 34.4 4.2 13.1 
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Chapter 6:  Discussion and Conclusions 
Our first experiment determined a reliable and efficient method to extract the 
OMBs from the intraperitoneal space. A peritoneal lavage catheter (JP7, Mila 
International) can be used for long term studies involving OMB treatment of rats with 
mild to severe ARDS. This catheter can be surgically implanted in the IP space and used 
for both infusion and scavenging of OMBs due to its flexibility, wide diameter, numerous 
pores, and increased length. In addition, this catheter can be used in experiments that 
requires extraction of OMBs from the IP space to test for CO2 absorption and O2 delivery 
by OMBs. 
Testing the effect of PMO as a potential therapy for ARDS requires at least 3 days 
of treatment. Thus, rats need to be conscious and able to move freely around their cage 
during this study. We have designed and developed an infusion system that automatically 
and intermittently infuses bolus dosage of OMBs to a rat’s IP cavity. The system will be 
used for studying PMO with conscious rats of mild to severe ARDS. We have completed 
a pilot study (n = 2) to verify the benefits of PMO therapy utilizing a continuous infusion 
device. There appears to be short-term improvement in reduction of hypoxia using pulse 
oximeter measurements of SpO2. However, the preliminary trial revealed advanced tissue 
obstruction and growth in the catheter after four days. This was a major problem as it 
prevented further removal of fluid from the cavity. Therefore, the design was revised to 
implement a periodic bolus system that is simpler and effective. This would allow OMBs 
to dwell in the cavity for gas exchange to occur between OMBs and peritoneum blood. 
Benchtop testing of the final design of the bolus delivery system has been successfully 
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completed. Since the tubing restraint was not working properly, a new design of a rat 
tether will be developed and tested shortly. In future trials, rats will be infused with either 
a bolus of sterile oxygenated saline, inert gas microbubbles (IMBs) as controls or OMBs 
for PMO therapy with four rats from each group. Upon completion of the device, we will 
evaluate the effect of PMO therapy on survival, lung health, and oxygen saturation. 
The significance of this study was to give a better understanding of how oxygen 
microbubbles exchange gas with peritoneal tissue when infused to the IP cavity. A model 
for diffusion predicted how fast oxygen will diffuse across the multiple layers of tissue in 
the surrounding abdomen and how that relate to the normal oxygen consumption need. In 
theory oxygen delivered by OMBs in vivo occurs at a range between 0.0045 and 0.038 
mL/s. This would supply between 4.2% and 34.4% of the total oxygen consumption 
needed in resting healthy rats.  
There are several limitations to this mathematical model. The O2 consumption by 
tissue in surrounding abdominal wall and internal organs was not accounted for. Oxygen 
consumption by tissue would decrease the amount of oxygen absorbed by blood 
capillaries. Also, it was assumed that OMBs maintain pure oxygen concentration, which 
was not the case in vivo because other gases diffuse into the bubbles as shown in the 
headspace gas measurements. The mathematical model was based on time and one 
dimensional space because of the complicated model schemes required for the true 
dynamics of diffusion in the 3D abdomen. 
The diffusion profile obtained from the in vivo study was compared to the 
modeled diffusion profile. The calculated diffusion zone (236 µm) was larger than the 
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thickness of the PM (90 µm), but less than the parenchymal tissue thickness (750 µm). 
This indicates that oxygen diffused past the PM to reach underlying tissue in the 
abdominal wall and internal organs, however oxygen did not diffuse to the entire depth of 
parenchymal tissue in rats (0.5-1 mm thick). In addition, the oxygen supplied by the 
OMBs (0.014 mL/s) was lower than the normal oxygen consumption of rats as expected 
because the study was conducted on healthy rats. In addition to having catheter problems 
using the continuous infusion system, these results changed our initial device design from 
continuous circulation of OMBs to bolus periodic delivery. A 60 mL OMB bolus would 
require a dwell time of approximately 45 min to reach steady state in gas exchange, but 
further in vivo tests are required to validate this dwell duration on ARDS rats. 
Pulse oximeter data indicated that bolus injection of OMBs did not cause any 
harm to the animal’s condition. General anesthesia causes low oxygen saturation and HR 
measured by peripheral pulse oximetry [52]. After 20 min, there was a slight increase in 
SpO2 by ~2.5%. This increase was statistically significant though it may not be clinically 
relevant.  These results indicate that peritoneal membrane oxygenation was not harmful 
and may be potentially effective in delivering oxygen to hypoxic rats. 
The greater decrease in oxygen content (Figure 5.4b) measured at 5 min 
compared to the 10 min sample could be due to air contamination. The outflow line was 
manually vacuumed directly after implantation into the IP cavity. Since this is not a 
perfect vacuum and it is unlikely that oxygen was reentering the OMBs, residual air 
within the line may explain why the sample taken at 10 min had more % O2 than the 5 
min sample. Another contributing factor could be that the gas volumes of the samples 
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was different. Fresh OMBs are composed of 70% O2, 30% saline, and <1% lipids. After 
OMBs dwell in the IP cavity, gas diffuses from OMBs to the body and vice versa thus 
changing the ratio of gas to saline volume. More oxygen diffused from OMBs than other 
gases being absorbed by the bubbles, so the gas percentage decreased gradually with 
time.  
One of the gases detected in OMBs was CO2, which cannot be due to air 
contamination because room air has only 0.003% CO2 [53]. This gives evidence that 
OMBs can uptake CO2 from the body. Healthy rats have a low blood concentration of 
CO2, which explains the low amount of CO2 detected in OMBs after dwelling in the IP 
cavity. Other traces of gases are unknown but assumed to be N2 because the nitrogen 
partial pressure in venous blood is 573 mmHg [54]. Venous PN2 is much greater than 
venous PCO2, PO2, and PH2O which are 46, 40, and 47 mmHg, respectively. Fresh OMBs 
have PO2 of 760 mmHg and PN2 of 0 mmHg ideally. Thus, there is a high blood-to-OMBs 
nitrogen pressure gradient that leads to a flux of N2 from surrounding venous tissue to 
OMBs dwelling in the IP space. This may be of great potential benefit for removal of 
excess nitrogen gas in decompression sickness, a common condition that affects divers 
[55]. Further testing will be conducted to validate the other gas(s) absorbed by OMBs. 
In conclusion, we developed a preliminary mathematical model that portrays the 
kinetics of oxygen transfer between OMBs and the body. In vivo results show that 
oxygen was delivered from OMBs by diffusive transport through the peritoneum into the 
adjacent blood and tissue of the abdominal wall and internal organs. CO2 was also able to 
diffuse from the body into OMBs. Also, peritoneal oxygenation with OMBs did not 
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negatively alter the physical condition of the rats. Both mathematical modeling and 
animal experiments were applied on healthy rats with normal levels of oxygenation and 
respiratory rate. This serves as a reference for future studies involving hypoxia. We are 
able to demonstrate in vivo that OMBs not only can provide O2 to the body, but also can 
absorb CO2 and possibly other gases, such as N2, from the body. This is very significant 
as it provides an alternative extrapulmonary technique of ventilation that can have 
significant implications in the future. 
Our future goals involve improving our model using advanced numerical methods 
or finite elements analysis (FEA) that would be more accurate in simulating diffusion of 
multiple gases [56]. The transport of O2, CO2, and N2 will also be modeled in hypoxic 
conditions. During hypoxemia, a lower oxygen concentration in blood increases the 
OMBs-to-blood oxygen concentration gradient thus increases the oxygen diffusion rate. 
In contrast, CO2 accumulation in blood and tissue during hypoxia will drive CO2 
diffusion in the opposite direction thus OMBs will absorb a higher amount of CO2. 
Future work will include in vivo experiments on a hypoxic rat model of acute 
respiratory distress syndrome where we predict faster transport of oxygen and a more 
significant removal of carbon dioxide from the body due to the respiratory system being 
compromised. The oxygen delivery rate will be evaluated in supplying enough oxygen to 
accommodate the compromised lungs. In addition, arterial blood gases will be taken 
before and after infusion of OMBs to rat’s IP cavity and tested for clinically significant 
increase in PaO2. 
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We will further study the potential side effects of infusing OMBs to the 
intraperitoneal space by conducting autopsy and toxicology tests of abdominal organs. In 
addition, one way to determine the fate of OMBs in vivo would be to radioactively label 
the lipids to test their absorption or breakdown. In addition, radioactive labeling O2 gas 
would be another way to detect the pathway of oxygen delivered by OMBs.  
The Berlin criteria used for classifying ARDS may also be used as a selection 
criteria for patients requiring peritoneal membrane oxygenation. PaO2/FiO2 is an 
important determinant of low levels of oxygen in blood. Further literature review and 
research need to be conducted to find a suitable selection criteria for ARDS patients 
requiring PMO. 
Patients with mild-to-moderate ARDS can be potentially treated with PMO either 
in tandem with current ventilation practices such as mechanical ventilation or by itself. 
Infusion of OMBs intraperitoneally would provide supplemental oxygenation to 
surrounding tissue in the abdomen and blood. Pulmonary ventilation supported by MV 
and supplemental extrapulmonary ventilation provided by PMO would supply enough 
oxygen that will hopefully prevent these patients to reach end stage ARDS. This would 
decrease the chance of these patients requiring ECMO, which has a high mortality rate. 
We foresee the implementation of peritoneal membrane oxygenation as a treatment and 
first response aid for respiratory distress in intensive care units and combat field settings 
in the future. 
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Appendix A: Aspirated OMB Volumes 
Table A.1 Recorded volumes of aspirated OMBs from IP space in rats (n = 5) 
 Volume of aspirated OMBs (mL) 
Rats 18G 16G 14G 11G 10G SOTT PLC 
1 0 0 0 1 0 1 30 
2 4 19 8 18 11 16 37 
3 0 23 1 0 6 11 33 
4 1 0 0 43 0 3 20 
5 4 35 0 0 0 7 30 
Mean ± SD 1.8 ± 2.1 15.4 ± 15.2 1.8 ± 3.5 12.4 ± 18.7 3.4 ± 4.5 7.6 ± 6.1 30 ± 6.3 
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Appendix B: Temperature Circuit Design  
 
 
Figure B.1 Temperature circuit board design using Altium 
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Appendix C: SolidWorks Drawings 
 
 
Figure C.1 Lower face dimensions of electronics box 
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Figure C.2 Top face dimensions of electronics box 
 
 
Figure C.3 Side face dimensions of electronic box  
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Appendix D: Modeling Program 
Matlab code for predicting the concentration change with time of peritoneum tissue after 
injection of OMBs.  
s = input('Please select case(1)/(2): '); 
if s == 1 
    x=0:.1:90;% thickness of PM (um) 
    y=0:.1:60; %time (seconds) 
else 
    x=0:1:750;% thickness of parenchymal tissue(um) 
    y=0:1:1800; 
end 
  
D = 1.7*10^3; %Diffusion coefficient of oxygen in tissue 
(um2/s) 
C0=0.12; % concentration of oxygen in plasma (ml/dl) 
Cs=2.286; % concentration of oxygen in peritoneal cavity 
filled with OMBs(ml/dl) 
  
figure(2); hold on 
n = length(x); 
  
for i = 150:150:n 
    X = x(i); 
    K = ((C0-Cs)* erf(X./(2*sqrt(D.*y)))+Cs); %Solution to 
Fick's second law where K is concentartion (ml/dl) 
    plot(y,K,'LineWidth',3); 
end 
xlabel('Time (seconds)','Fontsize',24) 
ylabel('O2 Concentration (mL/dL)','Fontsize',24) 
 
